Immune DIREcted and Cancer-selective immunoTherapy

Información del proyecto

I-DireCT

Identificador del acuerdo de subvención: 813871

DOI

10.3030/813871

Proyecto cerrado

Fecha de la firma de la CE 21 Agosto 2018

Fecha de inicio 1 Enero 2019

Fecha de finalización 30 Septiembre 2023

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 2 532 975,22

Aportación de la UE

€ 2 532 975,22

Coordinado por

ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (11)

Frontiers in Immunology EBook
List of PhDs theses
Presentations at Antibody engineering workshops 2

Special IDireCT sessions at international conferences workshops

Presentations at Antibody engineering workshops

Special IDireCT sessions at international conferences workshops

Characterization of new tumour-selective TNFR family-targeted drugs

Characterization of new tumourselective TNFR familytargeted drugs

List of publications I-DireCT

List of publications of all IDireCT members

Update 4 online knowledge bases
Update 2 online knowledge bases
Update 1 online knowledge bases
Identification and pre-clinical validation of tumour-targeted checkpoint drugs

Identification and preclinical validation of tumourtargeted checkpoint drugs

Update 3 online knowledge bases

Other (3)

Report on kick-off meeting
Press event
I-DireCT summer school

Websites, patent fillings, videos etc. (1)

Website

I-DireCT public website

Publicaciones

Peer reviewed articles (20)

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Autores: Ewa Cendrowicz; Lisa Jacob; Shirley Greenwald; Ami Tamir; Iris Pecker; Rinat Tabakman; Lucy Ghantous; Liat Tamir; Roy Kahn; Jasmine Avichzer; Alexandra Aronin; Shira Amsili; Elina Zorde-Khvalevsky; Yosi Gozlan; Martijn Vlaming; Gerwin Huls; Tom van Meerten; Michal Elhalel Dranitzki; Adam Foley-Comer; Yaron Pereg; Amnon Peled; Ayelet Chajut; Edwin Bremer
Publicado en: VOLUME=41;ISSN=0392-9078;TITLE=Journal of experimental & clinical cancer research, Edición 5, 2022, ISSN 1756-9966
Editor: BioMed Central Ltd
DOI: 10.1186/s13046-022-02256-x

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Autores: Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Publicado en: Scientific Reports, 2021, ISSN 2045-2322
Editor: Nature Publishing Group
DOI: 10.1038/s41598-021-00007-0

Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily

Autores: Kirstin Kucka, Harald Wajant
Publicado en: Frontiers in Cell and Developmental Biology, Edición 8, 2021, ISSN 2296-634X
Editor: Frontiers Media S.A.
DOI: 10.3389/fcell.2020.615141

Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics

Autores: Jimena Álvarez Freile; Ghizlane Choukrani; Kerstin Zimmermann; Edwin Bremer; Lars Dähne
Publicado en: Sensors and actuators b-Chemical, 346:130512. Elsevier Science, Edición 4, 2021, ISSN 0925-4005
Editor: Elsevier BV
DOI: 10.1016/j.snb.2021.130512

Development of vaterite particles for therapeutic protein drug delivery and pH-sensitive release mimicking the tumor microenvironment.

Autores: Ghizlane Choukrani, Jimena Álvarez Freile, Wei Wan, Gabriella Egri, Natasha Ustyanovska Avtenyuk (ESR2, UMCG/SURF), Valerie Wiersma, Edwin Bremer, Lars Dähne
Publicado en: Particle, 2021, ISSN 2571-712X
Editor: MDPI AG
DOI: 10.1002/ppsc.202100012

Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

Autores: Vinicio Melo, Edwin Bremer, John D. Martin
Publicado en: Frontiers in immunology, 2022, ISSN 1664-3224
Editor: Frontiers Media S.A.
DOI: 10.3389/fcell.2022.908389

CD24 is a potential immunotherapeutic target for Mantle Cell Lymphoma

Autores: Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, and Edwin Bremer
Publicado en: Biomedicines, 2022, ISSN 2227-9059
Editor: MDPI
DOI: 10.3390/biomedicines10051175

Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist

Autores: Kucka, Kirstin; Lang, Isabell; Zhang, Tengyu; Siegmund, Daniela; Medler, Juliane; Wajant, Harald
Publicado en: Cell Death and Disease, Vol 12, Iss 4, Pp 1-9 (2021), Edición 6, 2021, ISSN 2041-4889
Editor: Nature Publishing Group
DOI: 10.1038/s41419-021-03633-8

The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling

Autores: Vrouyr Bilemjian; Martijn R. Vlaming; Jimena Álvarez Freile; Gerwin Huls; Marco De Bruyn; Edwin Bremer
Publicado en: Cancer (Basel), Edición 9, 2023, ISSN 2072-6694
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers14133164

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism

Autores: Juliane Medler, Kirstin Kucka, Vinicio Melo, Tengyu Zhang, Stefan von Rotenhan, Jakob Ulrich, Edwin Bremer, Michael Hudecek, Andreas Beilhack, and Harald Wajant
Publicado en: Theranostics, 2022, ISSN 1838-7640
Editor: Ivyspring International Publisher
DOI: 10.7150/thno.66119

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

Autores: Ahmed Aido; Olena Zaitseva; Harald Wajant; Matej Buzgo; Aiva Simaite
Publicado en: Pharmaceutics, Edición 6, 2021, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13071072

Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance.

Autores: Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer and Valerie R. Wiersma.
Publicado en: Cell Death Discovery, 2023, ISSN 2058-7716
Editor: Nature Publishing Group
DOI: 10.1038/s41420-023-01515-w

Facing the Challenges of Pharmaceutical Research Using Whispering Gallery Modes-Based Biosensors

Autores: Lars Dähne
Publicado en: American Journal of Biomedical Science & Research, Edición 8/2, 2020, Página(s) 161-162, ISSN 2642-1747
Editor: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001259

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity

Autores: Natasha Ustyanovska Avtenyuk; Ghizlane Choukrani; Emanuele Ammatuna; Toshiro Niki; Ewa Cendrowicz; Harm Jan Lourens; Gerwin Huls; Valerie R. Wiersma; Edwin Bremer
Publicado en: Biomedicines, Vol 10, Iss 66, p 66 (2022), Edición 4, 2021, ISSN 2227-9059
Editor: MDPI
DOI: 10.3390/biomedicines10010066

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.

Autores: Zaitseva O, Hoffmann A, Löst M, Anany MA, Zhang T, Kucka K, Wiegering A, Otto C, Wajant H.
Publicado en: Frontiers in immunology, 2023, ISSN 1664-3224
Editor: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1194610

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Autores: Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer, Valerie R. Wiersma
Publicado en: International Journal of Molecular Sciences, Edición 21/21, 2020, Página(s) 7820, ISSN 1422-0067
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21217820

Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival

Autores: Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Vinicio Melo, Annechien Plat, Gerwin Huls, Hans W. Nijman, Marco de Bruyn, Edwin Bremer
Publicado en: Front. Immunol., 2022, ISSN 1664-3224
Editor: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1031746

Using Nanomedicine to Drive Advances in Cancer Immunotherapy: A Mini Review.

Autores: Choukrani G, Freile JA, Bremer E, Daehne L
Publicado en: American Journal of Biomedical Science & Research, 2020, ISSN 2642-1747
Editor: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001248

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Autores: Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, and Edwin Bremer
Publicado en: Frontiers in immunology, 2023, ISSN 1664-3224
Editor: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1191866

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Autores: Jimena Álvarez Freile; Yuzhu Qi; Lisa Jacob; Maria Franceskin Lobo; Harm Jan Lourens; Gerwin Huls; Edwin Bremer
Publicado en: Crossref, Edición 2, 2023, ISSN 1664-3224
Editor: Frontiers Media S.A
DOI: 10.3389/fimmu.2023.1233113

Thesis and dissertations (1)

Advancing Cancer Immunotherapy with Nanomedicine

Autores: Ghizlane Choukrani
Publicado en: 2023
Editor: University of Groningen
DOI: 10.33612/diss.660794643